These medications were the first agents of what is known as radioimmunotherapy, and they were approved for the treatment of refractory non-Hodgkins lymphoma.
Estes medicamentos foron os primeiros axentes do que se coñece como radioinmunoterapia, e foron aprobados para o tratamento do linfoma non de Hodgkins refractario.